ArticleCureus2025
Evaluation of the Glucocorticoid-Sparing Effect of Adding Methotrexate in Polymyalgia Rheumatica: A Single-Center Retrospective Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective This study assessed whether the addition of methotrexate (MTX) to glucocorticoid therapy reduces overall glucocorticoid usage in patients with polymyalgia rheumatica (PMR), focusing particularly on those exhibiting glucocorticoid-resistant disease. Methods This retrospective study included 82 patients with PMR treated with glucocorticoids. After applying matching weights, outcomes were compared between weighted populations of 18 patients receiving MTX and 18 receiving glucocorticoid monotherapy. A subgroup analysis was conducted among the 38 patients classified as glucocorticoid-resistant, comparing weighted populations of eight in the MTX group and nine in the non-MTX group after the application of matching weights. Results In the primary analysis (overall cohort), the cumulative glucocorticoid dose at 104 weeks was 4,263 mg in the MTX group and 4,418 mg in the non-MTX group, showing no significant reduction effect from MTX (mean difference, -155 mg; 95% confidence interval (CI), -1003 to 693; P = 0.717). The glucocorticoid discontinuation rate also showed no significant difference between the groups (38.2% vs. 27.8%; risk ratio (RR), 1.37; 95% CI, 0.61 to 3.1; P = 0.442). By contrast, in the subgroup analysis of glucocorticoid-resistant patients, the cumulative glucocorticoid dose in the MTX group was 4,298 mg, which was significantly lower than the 5,618 mg in the non-MTX group, with a mean difference of -1320 mg (95% CI, -2539 to -102; P = 0.035). The glucocorticoid discontinuation rate was also significantly higher in the MTX group than in the non-MTX group (45.5% vs. 4.1%; RR, 11; 95% CI, 2.1 to 57.9; P = 0.0059). Conclusions Although adjunctive MTX therapy did not significantly reduce glucocorticoid exposure in the overall PMR population, our findings suggest a substantial benefit for patients with glucocorticoid-resistant PMR, markedly reducing cumulative glucocorticoid exposure and increasing the rate of discontinuation. These results highlight the critical importance of patient selection when considering MTX for PMR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.